Antengene Corporation Limited (HKG:6996)

Hong Kong · Delayed Price · Currency is HKD

3.910

+0.050 (1.30%)

At close: Mar 6, 2026

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Research Development and Commercialisation of Pharmaceutical Products	91.95M	67.31M	160.14M	28.77M		11.03M
Research Development and Commercialisation of Pharmaceutical Products Growth	36.62%	-57.97%	456.62%	-		62.23%
Total	91.95M	67.31M	160.14M	28.77M		11.03M
Total Growth	36.62%	-57.97%	456.62%	-		62.23%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Mainland China	72.26M	56.70M	-	-		11.03M
Mainland China Growth	27.44%	-	-	-		62.23%
Other Countries/Regions	19.69M	10.61M	5.27M	238.00K		-
Other Countries/Regions Growth	85.69%	101.42%	2112.18%	-		-
Greater China	-	-	154.87M	28.53M		-
Greater China Growth	-	-	442.81%	-		-
Total	91.95M	67.31M	160.14M	28.77M		11.03M
Total Growth	36.62%	-57.97%	456.62%	-		62.23%

Source: S&P Global Market Intelligence.